论文部分内容阅读
目的：探讨ｎｍ２３表达与胃肠道平滑肌肿瘤（ＧＩＳＭＴ）良恶性、恶性程度、转移及预后的关系。方法：采用免疫组化Ｓ－Ｐ法检测了８６例ＧＩＳＭＴ中ｎｍ２３的表达情况。结果：ｎｍ２３的表达按平滑肌瘤、低度恶性平滑肌肉瘤、高度恶性平滑肌肉瘤的顺序依次明显下降（Ｐ＜０．０１）。同时，ｎｍ２３表达与肿瘤的良恶性生长方式、大小、中心有无坏死亦有明显的关系（Ｐ＜０．０１或Ｐ＜０．０５）。ｎｍ２３阳性表达组的５年生存率明显高于阴性表达组（Ｐ＜０．０５）。结论：ｎｍ２３是反映ＧＩＳＭＴ生物学特性的良好标志物，可以作为判断ＧＩＳＭＴ良恶性、恶性程度、转移及预后的客观指标。
Objective: To investigate the relationship between nm23 expression and benign and malignant gastrointestinal smooth muscle tumor (GISMT), malignancy, metastasis and prognosis. Methods: The expression of nm23 in 86 cases of GISMT was detected by immunohistochemical S-P method. RESULTS: The expression of nm23 was significantly decreased in the order of leiomyoma, low-grade leiomyosarcoma, and high-grade leiomyosarcoma (P<0.01). At the same time, nm23 expression was also significantly associated with benign and malignant tumor growth, size, and central necrosis (P<0.01 or P<0.05). The 5-year survival rate of the nm23-positive group was significantly higher than that of the negative-expressed group (P<0.05). Conclusion: nm23 is a good marker reflecting the biological characteristics of GISMT and can be used as an objective index to judge the benign, malignant, malignant degree, metastasis and prognosis of GISMT.